Innova Captab Ltd

INNOVACAP

Watchlist

AI Mode

‌

Market Cap

₹ 4,024 Cr

P/E

32.33

‌

Investment Checklist

How to read checklist?

Performance

STEADY PERFORMER

Valuation

OVERVALUED

Growth

EXCEPTIONAL

Profitability

MODERATE MARGIN

Technicals

Bearish

Risk

MODERATE RISK

Investment Checklist

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

Price

PE Ratio

Price

‌

Overview

Detailed Summary

Innova Captab Limited is an integrated pharmaceutical company in India involved in R&D, manufacturing, distribution, and marketing.

The company achieved a significant milestone by commencing operations at its state-of-the-art manufacturing facility in Kathua, Jammu, enhancing capacity and operational scale.

In Q2 and H1 FY26, Innova Captab reported a year-on-year revenue growth of 19.5%, highlighting strong operational execution and market demand.

Exports contribute 30% to the company's total revenue, reflecting a well-diversified geographic presence that supports its growth trajectory.

Despite challenges like declining API prices, the company achieved a 17% year-on-year growth in EBITDA for H1 FY26, showcasing resilience.

Sector

Pharmaceuticals

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln M/S

Market Cap

4,024 Cr

Volatility

High Risk

P/E Ratio

32.3

Industry P/E

30.8

PEG Ratio

1.2

P/B Ratio

3.9

52W High

1,259.00

52W Low

655.15

Sales CAGR

15.02%

15.82%

27.21%

10Y

—

Profit CAGR

35.94%

26.11%

35.69%

10Y

—

ROE

TTM

12.19%

14.06%

16.07%

10Y

—

ROCE

TTM

13.06%

16.10%

18.37%

10Y

—

Technicals

‌

Forecasts

No. of Analysts

6

1Y Price Target

824.67 ▲ 19.30%

Q3 EPS Estimate

Q3 Revenue Estimate

Unlock Premium Features

Price, EPS and Revenue Projections

Strong SellSellHoldBuyStrong Buy

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

updated on

Dec 03, 2025

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
ORCHPHARMA	822.85	4,173 Cr	79.88	3.28	0.00	4.10	4.28	3.02
SUVEN	177.30	4,034 Cr	—	14.34	0.00	-75.33	-75.33	-62.80
INNOVACAP	699.95	4,024 Cr	32.33	3.94	0.00	12.19	13.06	7.36
RPGLIFE	2375.00	3,923 Cr	35.20	7.08	1.01	20.12	26.21	30.53
DCAL	225.15	3,525 Cr	23.59	0.55	0.00	2.14	3.12	1.23
GUFICBIO	346.30	3,464 Cr	60.81	5.49	0.03	9.02	10.81	4.48
UNICHEMLAB	461.00	3,270 Cr	22.45	1.34	0.00	5.98	6.30	2.49

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

AI Mode

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Sales	233	283	302	263	294	318	316	315	352	380
Expenses	202	242	258	225	252	268	270	267	299	329
Operating Profit	31	40	45	38	42	50	47	48	52	52
OPM %	13.42	14.31	14.74	14.50	14.33	15.63	14.71	15.15	14.82	13.63
Other Income	1.13	3.34	2.34	5.69	2.12	2.22	4.33	3.38	4.48	4.19
Interest	5.03	8.81	6.80	0.81	0.14	0.15	0.17	1.95	2.86	5.50
Depreciation	2.79	4.83	4.93	3.41	4.85	4.99	5.13	9.80	11	11
Profit Before Tax	25	30	35	40	39	47	46	39	43	39
Tax %	28.50	24.12	28.64	27.36	25.01	25.23	24.96	24.78	27.32	24.39
Net Profit	18	23	25	29	29	35	34	30	31	30
EPS in Rs	—	4.77	4.39	5.02	5.15	6.12	5.97	5.17	5.42	5.18

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	356	373	411	801	926	1,081	1,244	1,301
Expenses	315	322	356	705	813	927	1,058	1,105
Operating Profit	41	51	54	96	114	154	186	196
OPM %	11.46	13.64	13.27	11.99	12.27	14.28	14.97	15.07
Other Income	0.22	1.30	1.37	2.88	9.20	12	12	14
Interest	5.58	4.63	3.93	5.68	20	21	2.41	5.13
Depreciation	11	10	5.59	7.50	11	16	25	31
Profit Before Tax	25	38	46	86	92	130	171	174
Tax %	19.74	25.70	25.56	25.39	25.97	27.16	25.00	25.57
Net Profit	20	28	35	64	68	94	128	130
EPS in Rs	—	—	—	—	—	17.85	22.41	21.74
Dividend Payout %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	12	12	12	12	48	57	57
Reserves	70	98	133	197	229	774	902
Borrowings	72	54	45	199	237	245	338
Other Liabilities	68	81	179	168	191	245	283
Total Liabilities	223	245	370	575	704	1,321	1,580
Fixed Assets	78	73	79	183	183	358	830
CWIP	0.00	0.00	7.26	0.03	22	341	23
Investments	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Assets	144	172	283	392	500	622	728
Total Assets	223	245	370	575	704	1,321	1,580

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	19	31	42	59	67	146	64
Cash from Investing Activity	-9.13	-6.04	-20	-188	-91	-499	-152
Cash from Financing Activity	-9.20	-23	-19	125	27	361	92
Net Cash Flow	0.54	1.48	2.56	-4.64	3.37	8.20	3.79

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Jun 2022	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Promoters	69.75%	50.90%	50.90%	50.90%	50.90%	50.90%	50.90%	50.90%	50.90%	50.90%
FIIs	0.00%	3.57%	3.57%	1.94%	1.19%	1.01%	0.74%	0.34%	0.23%	0.08%
DIIs	30.25%	11.73%	10.31%	20.77%	21.23%	20.61%	19.96%	19.76%	19.67%	20.17%
Public	0.00%	33.80%	35.22%	26.39%	26.68%	27.48%	28.41%	28.99%	29.20%	28.85%
Total Shareholders	7	1,39,154	1,39,117	39,396	35,115	32,254	36,692	39,996	41,014	40,245

Market Transactions

Date	Party	Category	Type	Avg Price (₹)	Total Value (₹)	Quantity	Percent Traded
Nov 18, 2025	Gian parkash aggarwal	Insider - Directors Immediate Relative	Pledge	752.45	21.07 Cr	2,80,000	0.48
Nov 18, 2025	Gian parkash aggarwal	Insider - Directors Immediate Relative	Pledge	752.45	18.81 Cr	2,50,000	0.43
Sep 29, 2025	Gian parkash aggarwal	Insider - Directors Immediate Relative	Pledge	856.05	81.32 Cr	9,50,000	1.65
Sep 29, 2025	Gian parkash aggarwal	Insider - Directors Immediate Relative	Pledge	822.00	106.86 Cr	13,00,000	2.27
Dec 29, 2023	Invesco mutual fund	Bulk	Buy	452.10	27.13 Cr	6,00,000	1.04
Dec 29, 2023	Mansi share & stock advisors ...	Bulk	Buy	539.00	10.80 Cr	2,00,438	0.35
Dec 29, 2023	Mansi share & stock advisors ...	Bulk	Sell	542.64	19.30 Cr	3,55,735	0.62
Dec 29, 2023	Mansi share and stock advisor...	Bulk	Sell	535.24	40.97 Cr	7,65,523	1.33
Dec 29, 2023	Elixir wealth management priv...	Bulk	Sell	512.06	14.51 Cr	2,83,277	0.49
Dec 29, 2023	Goldmine stocks private limited	Bulk	Sell	502.89	18.08 Cr	3,59,567	0.62

Projection

Unlock Premium Features

Get In-depth insights on EPS and Revenue forecasts

Actions

Action Type

‌
‌

Announcements

Last 7 days

Newest

Sentiment

Sorry, no results found!

Documents

Presentations

Concalls

Reports

Presentations

Investor Presentation

Q2 FY26

Investor Presentation

Q1 FY26

Investor Presentation

Q4 FY25

Investor Presentation

Q3 FY25

Investor Presentation

Q2 FY25

Investor Presentation

Q1 FY25

Investor Presentation

Q4 FY24

Investor Presentation

Q4 FY24

Showing 1 - 8 of 9

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

AI Mode

Oscillators

BearishNeutralBullish

Neutral

Bearish

Neutral

Bullish

Overall

BearishNeutralBullish

Bearish

Neutral

Bullish

Moving Averages

BearishNeutralBullish

Bearish

Neutral

Bullish

Overall

BearishNeutralBullish

Bearish

Neutral

Bullish

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
ORCHPHARMA	822.85	4,173 Cr	79.88	3.28	0.00	4.10	4.28	3.02
SUVEN	177.30	4,034 Cr	—	14.34	0.00	-75.33	-75.33	-62.80
INNOVACAP	699.95	4,024 Cr	32.33	3.94	0.00	12.19	13.06	7.36
RPGLIFE	2375.00	3,923 Cr	35.20	7.08	1.01	20.12	26.21	30.53
DCAL	225.15	3,525 Cr	23.59	0.55	0.00	2.14	3.12	1.23
GUFICBIO	346.30	3,464 Cr	60.81	5.49	0.03	9.02	10.81	4.48
UNICHEMLAB	461.00	3,270 Cr	22.45	1.34	0.00	5.98	6.30	2.49

Overview

Detailed Summary

Innova Captab Limited is an integrated pharmaceutical company in India involved in R&D, manufacturing, distribution, and marketing.

The company achieved a significant milestone by commencing operations at its state-of-the-art manufacturing facility in Kathua, Jammu, enhancing capacity and operational scale.

In Q2 and H1 FY26, Innova Captab reported a year-on-year revenue growth of 19.5%, highlighting strong operational execution and market demand.

Exports contribute 30% to the company's total revenue, reflecting a well-diversified geographic presence that supports its growth trajectory.

Despite challenges like declining API prices, the company achieved a 17% year-on-year growth in EBITDA for H1 FY26, showcasing resilience.

Sector

Pharmaceuticals

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln M/S

Market Cap

4,024 Cr

Volatility

High Risk

P/E Ratio

32.3

Industry P/E

30.8

PEG Ratio

1.2

P/B Ratio

3.9

52W High

1,259.00

52W Low

655.15

Sales CAGR

15.02%

15.82%

27.21%

10Y

—

Profit CAGR

35.94%

26.11%

35.69%

10Y

—

ROE

TTM

12.19%

14.06%

16.07%

10Y

—

ROCE

TTM

13.06%

16.10%

18.37%

10Y

—